381 related articles for article (PubMed ID: 24253546)
1. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil Cationic Protein, Carotid Plaque, and Incidence of Stroke.
Sundström J; Söderholm M; Borné Y; Nilsson J; Persson M; Östling G; Melander O; Orho-Melander M; Engström G
Stroke; 2017 Oct; 48(10):2686-2692. PubMed ID: 28904229
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
4. Cadmium, Carotid Atherosclerosis, and Incidence of Ischemic Stroke.
Borné Y; Fagerberg B; Persson M; Östling G; Söderholm M; Hedblad B; Sallsten G; Barregard L; Engström G
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29197829
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Borné Y; Persson M; Melander O; Smith JG; Engström G
Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
10. Carotid Atherosclerotic Plaque Characteristics on Magnetic Resonance Imaging Relate With History of Stroke and Coronary Heart Disease.
Selwaness M; Bos D; van den Bouwhuijsen Q; Portegies ML; Ikram MA; Hofman A; Franco OH; van der Lugt A; Wentzel JJ; Vernooij MW
Stroke; 2016 Jun; 47(6):1542-7. PubMed ID: 27165952
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of carotid plaque and risk of ischemic cardiovascular disease in the Chinese population.
Xie W; Wu Y; Wang W; Zhao D; Liang L; Wang M; Yang Y; Sun J; Shi P; Huo Y
J Am Soc Echocardiogr; 2011 Jul; 24(7):729-37. PubMed ID: 21440416
[TBL] [Abstract][Full Text] [Related]
12. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
[TBL] [Abstract][Full Text] [Related]
14. Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mortality: A systematic review and meta-analyses.
Gorgui J; Gasbarrino K; Georgakis MK; Karalexi MA; Nauche B; Petridou ET; Daskalopoulou SS
Metabolism; 2017 Apr; 69():51-66. PubMed ID: 28285652
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Engström G; Zöller B; Svensson PJ; Melander O; Persson M
Thromb Haemost; 2016 Mar; 115(3):657-62. PubMed ID: 26466866
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
[TBL] [Abstract][Full Text] [Related]
18. Increased carotid plaque burden in men with the fibrillin-1 2/3 genotype.
De Basso R; Hedblad B; Carlson J; Persson M; Ostling G; Länne T
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):637-42. PubMed ID: 24837032
[TBL] [Abstract][Full Text] [Related]
19. Orosomucoid, Carotid Plaque, and Incidence of Stroke.
Berntsson J; Östling G; Persson M; Smith JG; Hedblad B; Engström G
Stroke; 2016 Jul; 47(7):1858-63. PubMed ID: 27301938
[TBL] [Abstract][Full Text] [Related]
20. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
